Shares of BioNTech rose after the company said it plans to deliver over 2.2 billion vaccination doses this year.
Good news for BioNTech shareholders.
As of 1:00 p.m. today, the company's stock rose over 14 percent today after BioNTech said they signed agreements for about 2.2 billion doses this year.
In a press release, the company stated that along with partner Pfizer, they've crossed the one billion mark for COVID-19 vaccinations after only six months.
BioNTech also stated that over a billion doses have been ordered for 2022 and beyond.
Ugur Sahin, BioNTech Cofounder, also notes that they're expanding their vaccine supply to over 100 countries.
"To address the ongoing pandemic, we are expanding the supply of our COVID-19 vaccine to more than 100 countries and regions worldwide, including enhancing access to low- and middle-income countries. At the same time, we further developed our oncology pipeline, including the recent initiation of randomized Phase 2 trials for two FixVac programs."
The statement also says the companies are conducting multiple clinical trials on the effects of the vaccine on children between 6 months to 11 years old.
Moyer Farms Making $12M Investment
Niagara Falls Going Green for St. Patrick's Day
St. Catharines RIDE Campaign
Davies Challenges Gov't on EV Support
Welland's Plan for Hospital Contribution
New GO Station Coming to Niagara
Most Serious Collisions in Summer: Region
Coach Service Added to Airport